July 10, 2013

Keeping Score of Developing T1D


scoreResearchers are developing a way to score the chances of a person with certain autoantibodies to develop T1D. This exciting new approach was published in Diabetes Care.

Certain islet autoantibodies have been identified as causing a prediction of developing T1D. These islet autoantibodies are: GADA, IA-2A, and IAA. Islet cell cytoplasmic antibodies (ICA) has been a market used to measure how rapidly a person with new-onset T1D will lose beta cell function. But in the case of predicting T1D, it doesn’t  play an instrumental role.

The autoantibody risk score (ABRS) was strongly predictive of T1D. The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial–Type 1 Risk Score (DPTRS) predicted T1D more accurately at 2 years, than either the DPTRS or the ABRS alone.

These findings show the importance of knowing levels of islet autoantibodies in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D.

With this intel, we know who we’re watching. If predicting and preventing T1D becomes a play on strategy, how can we control the population of these antibodies? See the post on Commercializing a T1D Vaccine.

Visit Your Diabetes Health for more resources about health.